Polymyxins are antibiotics, with a general structure consisting of a cyclic peptide with a long hydrophobic tail. They disrupt the structure of the bacterial cell membrane by interacting with its phospholipids. They are produced by nonribosomal peptide synthetase systems in Gram-positive bacteria such as Paenibacillus polymyxa and are selectively toxic for Gram-negative bacteria due to their specificity for the lipopolysaccharide molecule that exists within many Gram-negative outer membranes. At least eleven different members of the polymyxin group have been identified and they are designated by a suffix letter. They demonstrate specific activity against gram-negative bacteria such as Proteus vulgaris, Escherichia coli, Hemophilus influenzae, Aerobacter aerogenes, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.
Polymyxins B and E (also known as colistin) are common types of polymyxins. Polymyxins B is used for the treatment of human Gram-negative bacterial infections, whil ...
Table of Contents
1 Market Overview
1.1 Polymixin Introduction
1.2 Market Analysis by Type
1.3 Market Analysis by Applications
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
126.96.36.199 United States Market States and Outlook (2014-2024)
188.8.131.52 Canada Market States and Outlook (2014-2024)
184.108.40.206 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
220.127.116.11 Germany Market States and Outlook (2014-2024)
18.104.22.168 France Market States and Outlook (2014-2024)
22.214.171.124 UK Market States and Outlook (2014-2024)
126.96.36.199 Russia Market States and Outlook (2014-2024)
188.8.131.52 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ...